Page 128 - Let them speak Towards a patient reported outcome measure set for

Chapter 5
References
1. American Psychiatric Association D, Association AP. Diagnostic and statistical manual of
mental disorders: DSM-5: American psychiatric association Washington, DC; 2013.
2. Leonard H, Wen X. The epidemiology of mental retardation: challenges and opportunities
in the new millennium. Mental retardation and developmental disabilities research reviews.
2002;8(3):117-34.
3. Wang J, Wang Y, Wang L, Chen WY, Sheng M. The diagnostic yield of intellectual disability:
combined whole genome low-coverage sequencing and medical exome sequencing. BMC
medical genomics. 2020;13:1-15.
4. Maulik PK, Mascarenhas MN, Mathers CD, Dua T, Saxena S. Prevalence of intellectual
disability: a meta-analysis of population-based studies. Research in developmental disabilities.
2011;32(2):419-36.
5. Robertson J, Hatton C, Emerson E, Baines S. Prevalence of epilepsy among people with
intellectual disabilities: a systematic review. Seizure. 2015;29:46-62.
6. Borkowska J, Schwartz RA, Kotulska K, Jozwiak S. Tuberous sclerosis complex: tumors and
tumorigenesis. International journal of dermatology. 2011;50(1):13-20.
7. Simonoff E, Pickles A, Wood N, Gringras P, Chadwick O. ADHD symptoms in children with
mild intellectual disability. Journal of the American Academy of Child & Adolescent Psychiatry.
2007;46(5):591-600.
8. Lubbers K, Stijl EM, Dierckx B, Hagenaar DA, Ten Hoopen LW, Legerstee JS, et al. Autism
symptoms in children and young adults with fragile x syndrome, angelman syndrome,
tuberous sclerosis complex, and neurofibromatosis type 1: a cross-syndrome comparison.
Frontiers in Psychiatry. 2022;13:852208.
9. Tye C, Mcewen FS, Liang H, Underwood L, Woodhouse E, Barker ED, et al. Long‐term cognitive
outcomes in tuberous sclerosis complex. Developmental Medicine & Child Neurology.
2020;62(3):322-9.
10. Schneider M, Armando M, Pontillo M, Vicari S, Debbané M, Schultze‐Lutter F, et al. Ultra high
risk status and transition to psychosis in 22q11. 2 deletion syndrome. World psychiatry.
2016;15(3):259-65.
11. Muscogiuri G, Barrea L, Faggiano F, Maiorino M, Parrillo M, Pugliese G, et al. Obesity in
Prader–Willi syndrome: Physiopathological mechanisms, nutritional and pharmacological
approaches. Journal of Endocrinological Investigation. 2021;44(10):2057-70.
12. Jansen S, Hoischen A, Coe BP, Carvill GL, Van Esch H, Bosch DG, et al. A genotype-first approach
identifies an intellectual disability-overweight syndrome caused by PHIP haploinsufficiency.
European journal of human genetics. 2018;26(1):54-63.
13. Taheri A, Perry A, Minnes P. Examining the social participation of children and adolescents
with intellectual disabilities and autism spectrum disorder in relation to peers. Journal of
Intellectual Disability Research. 2016;60(5):435-43.
14. Simões C, Santos S. Comparing the quality of life of adults with and without intellectual
disability. Journal of Intellectual Disability Research. 2016;60(4):378-88.
15. Edwards G, Jones C, Pearson E, Royston R, Oliver C, Tarver J, et al. Prevalence of anxiety
symptomatology and diagnosis in syndromic intellectual disability: A systematic review and
meta-analysis. Neuroscience & Biobehavioral Reviews. 2022;138:104719.
16. Agar G, Brown C, Sutherland D, Coulborn S, Oliver C, Richards C. Sleep disorders in rare genetic
syndromes: a meta-analysis of prevalence and profile. Molecular autism. 2021;12:1-17.
17. Huisman S, Festen D, Bakker‐van Gijssel E. Healthcare for people with intellectual disabilities in
the Netherlands. Journal of Policy and Practice in Intellectual Disabilities. 2024;21(2):e12496.
18. van Eeghen AM, Bruining H, Wolf NI, Bergen AA, Houtkooper RH, van Haelst MM, et al.
Personalized medicine for rare neurogenetic disorders: can we make it happen? Molecular
Case Studies. 2022;8(2):a006200.
19. Benjamin K, Vernon MK, Patrick DL, Perfetto E, Nestler-Parr S, Burke L. Patient-reported
outcome and observer-reported outcome assessment in rare disease clinical trials: an ISPOR
COA emerging good practices task force report. Value in Health. 2017;20(7):838-55.
20. Gibbons C, Porter I, Goncalves-Bradley DC, Stoilov S, Ricci-Cabello I, Tsangaris E, et al. Routine
provision of feedback from patient-reported outcome measurements to healthcare providers
and patients in clinical practice. Cochrane Database Syst Rev. 2021;10:CD011589.
21. Rivera SC, Kyte DG, Aiyegbusi OL, Slade AL, McMullan C, Calvert MJ. The impact of patient-
reported outcome (PRO) data from clinical trials: a systematic review and critical analysis.
Health and quality of life outcomes. 2019;17:1-19.
126